The biotech sector is experiencing the most severe downturn of at least the last 20 years. There have been many other downturns in the more recent past, but this one is different. Here Peter Kolchinsky discusses why - and how we’ll rebound.

When a biotech company is valued at around the same amount of cash it has sitting in the bank, is it a safe investment? Some investors might think so - and so we looked at the data. The answer might surprise you.

Created through the fusion of parallel efforts at RA Capital and Atlas Venture, TRIANA is a newly launched biotech that is building its pipeline using a target-first, rational approach to molecular glue discovery.

Gateway is RA Capital’s new board-building tool. It’s free to use, so give it a try. And if you’re on a biotech board or aspire to be on one, please take a minute to fill out a profile.

Take a few minutes at the beginning of a board meeting to give the board the big picture before asking them to analyze individual pieces of your narrative. At RA Capital, we encourage our companies to use a tool called the Elephant Slide. This slide helps visualize a company’s value proposition, goals, challenges, and upcoming decisions in one place - allowing you to address the elephant in the room.

Biotech board members and management teams are increasingly asking how their companies can benefit from what RA Capital and others call a “Series I” IPO process (also known as a data-driven or logic-based IPO). Here we’ve compiled common questions and answers.

Covid has flooded a barren vaccine startup landscape with capital. And that has revealed some valuable lessons for investors, company builders, Congress, and the public.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

Interest in life science technologies and tools is accelerating with the advent of CRISPR and other aspects of synthetic biology. The ability to have a capital efficient way to advance these innovations is very attractive and will help drive innovation.

The so-called venture creation model has fully taken root, underpinned and enabled by biotech's longest-ever boom cycle and unprecedented sums of available capital.

Whatever therapy or intervention solves a previously unmet need is inherently novel. So any treatments for COVID-19 that turn out to work will be "novel" in every way that matters.